What Price Pain Relief?
- 27 June 2006
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (25) , 2868-2870
- https://doi.org/10.1161/CIRCULATIONAHA.106.634386
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial InfarctionCirculation, 2006
- How the US Drug Safety System Should Be ChangedPublished by American Medical Association (AMA) ,2006
- Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular EventsCirculation, 2006
- Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugsExpert Opinion on Drug Safety, 2005
- Cyclooxygenase Inhibition and Cardiovascular RiskCirculation, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialThe Lancet, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Acute respiratory-tract infections and risk of first-time acute myocardial infarctionThe Lancet, 1998
- Large-scale randomized evidence: Large, simple trials and overviews of trialsJournal of Clinical Epidemiology, 1995